Rutgers University Study of the Genetics of Blood Cancers

July 15, 2026 updated by: Tara Matise, Ph.D., Rutgers, The State University of New Jersey

The Rutgers University Study of the Genetics of Blood Cancers

The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

This is an online research study to learn more about how genes affect your risk of blood cancers. No office visit is required and in return, participants may receive information about their genetic ancestry for free. This study will increase our understanding of the genetic basis of blood cancers, which is a crucial step in drug development to improve current treatment options. We seek a diverse population because diversity among participants maximizes the usefulness of the data. Participants will use our online study portal to answer questions about their health and provide their DNA via a saliva sample using a pre-paid mailer. Participation takes approximately 20 minutes. Participants will be invited to share data from their electronic health records, but this is not required for study participation. We keep participants engaged with short monthly newsletters.

Study Type

Observational

Enrollment (Estimated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • New Jersey
      • Piscataway, New Jersey, United States, 08854
        • Rutgers University
        • Contact:
        • Principal Investigator:
          • Tara Matise, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population consists of anyone at least 18 years old who lives in the United States, including both individuals who have or had blood cancer and those who have not. Participants include males, females, non-binary, and all race-ethnic groups.

Description

Inclusion Criteria:

  • age 18 years or older
  • currently living in the United States
  • have access to the internet and a computer, laptop, tablet or smartphone
  • willing to provide written informed consent for participation
  • willing to provide DNA via a saliva sample using a collection kit mailed to your home
  • willing to complete a survey with questions about health related to the study of blood cancer.

Exclusion Criteria:

  • Not able to meet or fulfill any of the inclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Cases
Persons with blood cancer
Controls
Persons who do not have blood cancer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Genetic risk variants associated with blood cancer
Time Frame: 2 years
Genetic factors will be measured through whole exome sequencing and genome-wide genotyping array, and then correlated with blood cancer subtype.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rutgers, The State University of New Jersey

Investigators

  • Principal Investigator: Tara Matise, PhD, Rutgers University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

August 1, 2029

Study Completion (Estimated)

August 1, 2029

Study Registration Dates

First Submitted

July 15, 2026

First Submitted That Met QC Criteria

July 15, 2026

First Posted (Actual)

July 20, 2026

Study Record Updates

Last Update Posted (Actual)

July 20, 2026

Last Update Submitted That Met QC Criteria

July 15, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Pro2026000226

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Our study protocol does not include sharing IPD.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe